Before revision: In March 2024, pemivibart, a monoclonal antibody drug, received an emergency use authorization from the US FDA to protect certain moderately to severely immunocompromised individuals against COVID-19.
After revision: for use as pre-exposure prophylaxisIn March 2024, pemivibart, a monoclonal antibody drug, received an emergency use authorization from the US FDA to protect certain moderately to severely immunocompromised individuals against COVID-19.